ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 171 filers reported holding ARRAY BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $405,492,000 | +51.6% | 8,752,254 | -20.2% | 11.47% | +46.6% |
| Q1 2019 | $267,461,000 | +14.0% | 10,970,518 | -33.3% | 7.83% | -17.0% |
| Q4 2018 | $234,543,000 | -3.0% | 16,459,128 | +3.5% | 9.43% | +26.8% |
| Q3 2018 | $241,782,000 | -9.8% | 15,906,680 | -0.4% | 7.44% | -18.3% |
| Q2 2018 | $268,121,000 | -4.6% | 15,978,580 | -7.2% | 9.11% | -16.1% |
| Q1 2018 | $281,103,000 | +14.9% | 17,224,428 | -9.9% | 10.86% | +2.1% |
| Q4 2017 | $244,657,000 | +13.3% | 19,113,864 | +8.9% | 10.64% | -0.2% |
| Q3 2017 | $215,946,000 | +60.3% | 17,556,586 | +9.1% | 10.65% | +29.9% |
| Q2 2017 | $134,705,000 | +18.0% | 16,093,786 | +26.1% | 8.20% | +10.7% |
| Q1 2017 | $114,127,000 | -21.9% | 12,765,862 | -23.2% | 7.41% | -41.2% |
| Q4 2016 | $146,079,000 | +29.9% | 16,618,776 | -0.2% | 12.59% | +40.8% |
| Q3 2016 | $112,442,000 | +64.9% | 16,658,072 | -13.0% | 8.94% | +37.3% |
| Q2 2016 | $68,176,000 | +20.7% | 19,150,650 | 0.0% | 6.51% | +12.6% |
| Q1 2016 | $56,494,000 | -25.0% | 19,150,650 | +7.3% | 5.78% | +2.6% |
| Q4 2015 | $75,330,000 | -6.9% | 17,850,650 | +0.6% | 5.64% | -8.1% |
| Q3 2015 | $80,942,000 | -17.6% | 17,750,510 | +30.3% | 6.13% | -23.8% |
| Q2 2015 | $98,226,000 | +1.5% | 13,623,620 | +3.8% | 8.05% | -7.3% |
| Q1 2015 | $96,736,000 | +72.5% | 13,125,594 | +10.7% | 8.69% | +42.2% |
| Q4 2014 | $56,090,000 | +88.3% | 11,858,294 | +42.2% | 6.11% | +77.5% |
| Q3 2014 | $29,781,000 | -19.2% | 8,342,045 | +3.2% | 3.44% | -23.1% |
| Q2 2014 | $36,872,000 | +60.7% | 8,085,945 | +65.6% | 4.47% | +63.2% |
| Q1 2014 | $22,950,000 | +2.7% | 4,882,930 | +9.5% | 2.74% | -0.7% |
| Q4 2013 | $22,348,000 | -2.1% | 4,460,688 | +21.6% | 2.76% | -19.8% |
| Q3 2013 | $22,825,000 | +5.4% | 3,669,593 | -23.1% | 3.44% | -9.9% |
| Q2 2013 | $21,653,000 | -6.6% | 4,769,368 | +1.0% | 3.82% | -10.4% |
| Q1 2013 | $23,195,000 | – | 4,724,020 | – | 4.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |